Cellectis SA (CLLS)
1.86
-0.05
(-2.62%)
USD |
NASDAQ |
Nov 21, 16:00
1.88
+0.02
(+1.08%)
Pre-Market: 20:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 186.17M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -34.51% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 5.732 |
Price to Book Value | 1.438 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.3579 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 97.08% |
Profile
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications. |
URL | https://www.cellectis.com |
Investor Relations URL | https://www.cellectis.com/en/investors |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | Small Cap/Value |
Next Earnings Release | Apr. 29, 2025 (est.) |
Last Earnings Release | Nov. 04, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications. |
URL | https://www.cellectis.com |
Investor Relations URL | https://www.cellectis.com/en/investors |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | Small Cap/Value |
Next Earnings Release | Apr. 29, 2025 (est.) |
Last Earnings Release | Nov. 04, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |